Enovis (NYSE:ENOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

by · The Markets Daily

Enovis (NYSE:ENOV – Get Free Report) announced its quarterly earnings results on Thursday. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05, FiscalAI reports. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million for the quarter, compared to analyst estimates of $581.84 million. During the same quarter last year, the firm posted $0.79 earnings per share. The business’s revenue for the quarter was up 3.2% on a year-over-year basis. Enovis updated its FY 2026 guidance to 3.520-3.730 EPS.

Here are the key takeaways from Enovis’ conference call:

  • Second-quarter organic sales grew 5%, led by 6% growth in Recon and 3% in PNR. U.S. Recon hips and knees and extremities each grew 8% in the first half, while Nebula, ARG, and the full commercial launch of ARVIS are gaining traction.
  • Adjusted gross margin improved 120 basis points on an underlying basis, and adjusted EBITDA margin rose 70 basis points to 17.9%. Management cited favorable product mix, productivity, and Lima integration synergies, and expects continued multi-year margin expansion.
  • Free cash flow improved by $27 million year over year to $31 million in the quarter, bringing first-half cash flow slightly positive. The company reaffirmed its target of greater than 25% free-cash-flow conversion for 2026 and aims to reduce leverage below 3x.
  • Enovis reaffirmed its 2026 guidance but expects a seasonally weaker-than-usual third quarter because of softer Western European markets and Middle East-related disruption, followed by sales acceleration in the fourth quarter.
  • Inflationary pressure from raw materials, freight, distribution, and the Middle East conflict reduced second-quarter results by $2 million and is expected to total a $10 million full-year impact. Management said passing through additional costs remains difficult, particularly in PNR, because of competitive and market pressures.

Enovis Stock Performance

Shares of NYSE:ENOV traded up $0.38 on Friday, hitting $26.68. 2,058,436 shares of the company were exchanged, compared to its average volume of 1,111,529. The firm has a market capitalization of $1.54 billion, a P/E ratio of -1.39 and a beta of 1.34. The company has a current ratio of 1.98, a quick ratio of 1.05 and a debt-to-equity ratio of 0.84. Enovis has a 1-year low of $19.14 and a 1-year high of $34.28. The stock’s 50 day moving average price is $24.62 and its 200 day moving average price is $23.97.

More Enovis News

Here are the key news stories impacting Enovis this week:

  • Positive Sentiment: Enovis reported second-quarter adjusted earnings of $0.90 per share, above the $0.85 analyst consensus and up from $0.79 a year earlier. Revenue of $582.8 million was also slightly ahead of estimates, while sales increased 3.2% year over year. Enovis Q2 Earnings and Revenue Estimates
  • Positive Sentiment: Management reaffirmed its full-year 2026 outlook, including revenue of approximately $2.3 billion to $2.4 billion and adjusted EPS guidance of $3.52 to $3.73. Reconstructive sales were a relative bright spot, rising 8% on a reported basis and 6% organically. Enovis Announces Second Quarter 2026 Results
  • Positive Sentiment: BTIG Research raised its price target from $39 to $40 and maintained a Buy rating, implying substantial potential upside from recent trading levels. BTIG Research Price Target
  • Neutral Sentiment: Wells Fargo lowered its price target modestly from $40 to $39 but retained an Overweight rating, indicating continued long-term confidence despite near-term concerns. Wells Fargo Price Target
  • Negative Sentiment: The market reaction was negative because Enovis’ second-quarter performance was characterized as “softer than expected.” Although revenue and EPS exceeded published estimates, investors appear focused on the relatively modest 3% reported sales growth and the lack of an upward guidance revision. Enovis Shares Drop After Second-Quarter Earnings
  • Negative Sentiment: Enovis continues to report a deeply negative GAAP net margin, which may reinforce investor concerns about profitability and execution even though adjusted earnings improved. Enovis Q2 2026 Earnings Call Transcript

Insider Activity

In other news, insider Oliver Engert bought 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders acquired 4,200 shares of company stock valued at $92,084. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ENOV. Arax Advisory Partners purchased a new position in shares of Enovis in the fourth quarter worth about $29,000. EverSource Wealth Advisors LLC boosted its position in Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares during the last quarter. Danske Bank A S acquired a new position in Enovis in the 3rd quarter worth approximately $64,000. iSAM Funds UK Ltd acquired a new position in Enovis in the 3rd quarter worth approximately $80,000. Finally, Brown Brothers Harriman & Co. purchased a new position in Enovis during the 3rd quarter worth approximately $90,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on ENOV shares. Wells Fargo & Company dropped their price objective on shares of Enovis from $40.00 to $39.00 and set an “overweight” rating on the stock in a research note on Friday. Evercore set a $32.00 price target on Enovis in a research report on Monday, July 6th. UBS Group reaffirmed a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Finally, BTIG Research boosted their target price on shares of Enovis from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Enovis currently has a consensus rating of “Moderate Buy” and an average price target of $42.00.

Get Our Latest Research Report on ENOV

Enovis Company Profile

(Get Free Report)

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.

Featured Stories